Overview
- The companies announced on Monday that AbbVie agreed to pay $135.11 per share in cash for Apogee, with unanimous board approvals and a target close in the third quarter of 2026 pending regulatory clearances and an Apogee shareholder vote.
- The acquisition centers on zumilokibart, an IL-13–blocking antibody whose Phase 2 data showed about two-thirds of patients achieved major skin clearance at 16 weeks and that supports quarterly or twice-yearly maintenance dosing; the drug is now in Phase 3 studies.
- AbbVie will finance the purchase with debt and the transaction’s net implied value is about $10.1 billion after subtracting Apogee’s cash; published estimates show a near-term hit to adjusted EPS before the deal is forecast to become accretive over several years.
- Markets immediately repriced on the news with Apogee shares jumping roughly 47–48% and AbbVie moving modestly, and analysts including JPMorgan called the fit strategic while warning the outcome depends on Phase 3 results and execution.
- The deal reflects AbbVie’s push to replenish its immunology pipeline as Humira sales decline and investors should watch upcoming Phase 3 readouts, regulatory reviews, and how AbbVie integrates Apogee’s programs for patient access and commercial launch.